Characteristics of bone remodeling in female ovariectomized rat models of osteoporosis undergoing Erzhi Pill extract intervention

doi:10.3969/j.issn.2095-4344.2975

Abstract

Abstract: BACKGROUND: Some studies have shown that Erzhi Pill can improve the bone density, bone shadow area, bone mineral content and serum estradiol level of ovariectomized rats, but the possible mechanism has not been explored.
OBJECTIVE: To investigate the effect of Erzhi Pill on bone remodeling in an ovariectomized rat model of osteoporosis.
METHODS: A rat model of post-menopausal osteoporosis was established, and the extracts of Erzhi Pills of 6, 9, and 12 g/kg per day were administered intragastrically. Administration in each group began at the 13th week after surgery, and the samples were taken at 16, 20, and 24 weeks after surgery. The bone tissue morphology was observed by hematoxylin-eosin staining, the percentage of trabecular bone was measured by Motic 6.0 system, and the bone density of the rat right tibial bone was detected by a bone densitometer. Expressions of osteoprotegerin, nuclear factor κB receptor activating factor ligand (RANKL), tartrate-resistant acid phosphatase (TRAP) and osteocalcin mRNAs in the first lumbar vertebrae were detected by qPCR.

RESULTS AND CONCLUSION: The trabecular bone had a better morphological structure, and the number of trabeculae, bone miner density, and bone tissue osteoprotegerin level were significantly increased in a dose-depended manner after treatment with Erzhi Pill, whereas the mRNA levels of RANKL and TRAP decreased in a dose-depended manner after treatment with Erzhi Pill (P < 0.05). Therefore, the alcohol extract of Erzhi Pill can improve the status of high-transformation osteoporosis in ovariectomized rats, promote the expression of osteoprotegerin and inhibit the expression of RANKL, so as to inhibit the activity of osteoclasts and ultimately improve the bone remodeling in female osteoporotic rats.

Key words: Erzhi Pills, postmenopausal osteoporosis, rat, castration, osteocalcin, osteoprotegerin, bone morphology, bone remodeling

CLC Number:

Li Ping, Lin Yu, Chen Xiang, Liu Zhentao, Xiao Lili, Lin Xueyi, Hua Peng . Characteristics of bone remodeling in female ovariectomized rat models of osteoporosis undergoing Erzhi Pill extract intervention[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(2): 191-195.

Figures/Tables 7

References

[1] Curtis EM, Moon RJ, Harvey NC, et al. Reprint of: the impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone. 2017;104:29-38.
[2] Borrelli J. Taking control: the osteoporosis epidemic. Injury. 2012; 43(8):1235-1236.
[3] Ballane G, Cauley JA, Luckey MM, et al. Secular trends in hip fractures worldwide: opposing trends East versus West. J Bone Miner Res. 2014;29(8):1745-1755.
[4] Chen P, Li Z, Hu Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review. BMC Public Health. 2016;16(1):1039.
[5] Marini F, Cianferotti L, Brandi ML. Epigenetic mechanisms in bone biology and osteoporosis: can they drive therapeutic choices? Int J Mol Sci. 2016;17(8):1329.
[6] Chen K, Yuan Y, Wang Z, et al. Helvolic acid attenuates osteoclast formation and function via suppressing RANKL-induced NFATc1 activation. J Cell Physiol. 2019;234(5):6477-6488.
[7] Kim B, Lee KY, Park B. Icariin abrogates osteoclast formation through the regulation of the RANKL-mediated TRAF6/NF-kappaB/ERK signaling pathway in Raw264.7 cells. Phytomedicine. 2018;51:181-190.
[8] 国家药典委员会.中华人民共和国药典(一部):2010年版[S].北京:中药医药科技出版社, 2010:351-352.
[9] 黄新苹,王武朝.中药女贞子的化学成分研究进展[J].国际药学研究杂志,2011,38(1):47-51.
[10] 林雄浩,吴锦忠.中药复方二至丸的化学成分及抗骨质疏松研究进展[J].解放军药学学报,2009,25(5):421-424.
[11] Ikeda Y, Yonemitsu I, Takei M, et al. Mechanical loading leads to osteoarthritis-like changes in the hypofunctional temporomandibular joint in rats. Arch Oral Biol. 2014;59(12):1368-1376.
[12] Wolski H, Drews K, Bogacz A, et al. The RANKL/RANK/OPG signal trail: significance of genetic polymorphisms in the etiology of postmenopausal osteoporosis. Ginekol Polska. 2016;87(5):347-352.
[13] Sun X, Wei B, Peng ZH, et al. Protective effects of Dipsacus asper polysaccharide on osteoporosis in vivo by regulating RANKL/RANK/OPG/VEGF and PI3K/Akt/eNOS pathway. Int J Biol macromol. 2019;129(15):579-587.
[14] 李冠慧,黄明芳,李西海,等.基于肾主骨生髓探讨骨髓基质干细胞与绝经后骨质疏松肾虚证的关系[J].中国老年学, 2016,36(15): 3846-3848.
[15] 张明发, 沈雅琴.女贞子及其活性成分抗骨质疏松症的研究进展[J].药物评价研究, 2014,37(6):566-571.
[16] Zhang Y, Lai WP, Leung PC, et al. Effects of Fructus Ligustri Lucidi extract on bone turnover and calcium balance in ovariectomized rats. Biol Pharm Bull. 2006;29(2):291-296.
[17] Crockett JC, Rogers MJ, Coxon FP, et al. Bone remodelling at a glance. J Cell Sci. 2011;124(7):991-998.
[18] Matsuo K, Otaki N. Bone cell interactions through Eph/ephrin:
bone modeling, remodeling and associated diseases. Cell Adh Migr. 2012;30:148-156.
[19] Gossiel F, Paggiosi MA, Naylor KE, et al. The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: the T-score bone marker approach in the TRIO study. Bone. 2020;131:115158.
[20] Sampson TG. Arthroscopic treatment for chondral lesions of the hip. Clin Sports Med. 2011;30(2):331-348.
[21] Li XL, Liu DQ, Li J, et al. Wnt3a involved in the mechanical loading on improvement of bone remodeling and angiogenesis in a postmenopausal osteoporosis mouse model. FASEB J. 2019;33(8): 8913-8924.
[22] Zhou L, Liu Q, Yang M, et al. Dihydroartemisinin, an anti-malaria drug, suppresses estrogen deficiency-induced osteoporosis, osteoclast formation, and RANKL-induced signaling pathways. J Bone Miner Res. 2016;31(5):964-974.
[23] 陈楠,李晓莉,张岩.女贞子及其活性成分抗骨质疏松作用及途径研究进展[J].中国药理学通报,2018,34(8):1057-1060.
[24] 李晓曦,陈宇恒,唐秀凤,等.基于雌激素作用的淫羊藿女贞子配伍对绝经后骨质疏松症大鼠的影响研究[J].中国中医骨伤科杂志, 2019, (9):1-6, 10.
[25] Fellah F, Djenidi R, Chebout I. Protective effect of sphaerococcus coronopifolius crude extract in combination with bacillus calmette-guerin on ligature-induced depression in female wistar rats. Psychiatry Investig. 2020;17(2):130-139.
[26] Song DZ, Cao Z, Huang S, et al. Achyranthes bidentata polysaccharide suppresses osteoclastogenesis and bone resorption via inhibiting RANKL signaling. J Cell Biochem. 2018;18:266-282.
[27] Zhang Y, Li J X, Zhao J, et al. Synthesis and activity of oleanolic acid derivatives, a novel class of inhibitors of osteoclast formation. Bioorg Med Chem Lett. 2005;15(6):1629-1632.
[28] Meng YQ, Kuai ZY, Zhan SW, et al. Design, synthesis, and antitumor activity of oleanolic acid derivatives. J Asian Nat Prod Res. 2018;21(7): 633-651.
[29] 肖宗崇.二至丸配方颗粒汤剂与其传统汤剂化学成分及药效学比较研究[D].广州:广州中医药大学,2017.